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ABSTRACT 
 
Currently, there are several treatments for osteoporosis however; they all display 
some sort of limitation and/or side effects making the need for new treatments 
imperative. We have previously demonstrated that NMP is a bioactive drug which 
enhances bone regeneration in vivo and acts as an enhancer of bone morphogenetic 
protein (BMP) in vitro. NMP also inhibits osteoclast differentiation and attenuates 
bone resorption.   
In the present study, we tested NMP as a bromodomain inhibitor and for osteoporosis 
prevention on ovariectomized (OVX) induced rats while treated systemically with 
NMP. Female Sprague- Dawley rats were ovariectomized and weekly NMP treatment 
was administrated 1 week after surgery for 15 weeks. Bone parameters and related 
serum biomarkers were analyzed. 15 weeks of NMP treatment decreased 
ovariectomy-induced gained weight in average by 43% and improved bone mineral 
density (BMD) and bone volume over total volume (BV/TV) in rat femur in average by 
25% and 41% respectively. Moreover, mineral apposition rate and bone biomarkers 
of bone turnover in the treatment group were at similar levels with those of the Sham 
group.  
Due to the function of NMP as a low affinity bromodomain inhibitor and its 
mechanism of action involving osteoblasts/osteoclasts balance and inhibitory effect 
on inflammatory cytokines, NMP is a promising therapeutic compound for the 
prevention of osteoporosis. 
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1. INTRODUCTION 
 
Osteoporosis is a skeletal disorder characterized by compromised bone strength 
that predisposes to increased risk of fracture. It is most often caused by an increase 
in bone resorption that is not sufficiently compensated for by a corresponding 
increase in bone formation [1]. 
Osteoporosis poses a significant public health issue. It is estimated that over 200 
million are affected by osteoporosis worldwide. The number of women with 
osteoporosis and subsequent fractures are bound to rise as the elderly population 
increases [2]. Advanced age and early menopause are the best predictors of 
osteoporosis, but other factors such as; low body weight, diseases, treatments, family 
history of osteoporosis and inactive lifestyle increase susceptibility to fractures [3]. 
The cost of osteoporosis-related fractures to the economy is enormous,  predicted to 
escalate to $131.5 billion by 2050 [4]. In Europe alone 22 million women and 5.5 
million men are estimated to have osteoporosis [5]. Because of the vast medical and 
socioeconomic challenges that osteoporosis present worldwide; the need for new 
treatments is both imperative and pressing.  
At the moment, some of the most used therapies for osteoporosis include, but are 
not limited to, bisphosphonates, parathyroid hormone (PTH), and selective estrogen 
receptor modulators (SERMs). Over the last decade, as bisphosphonates became an 
established treatment for osteoporosis, potential side effects of patients under this 
therapy have been reported. The most common includes atypical subtrochanteric or 
femoral shaft fractures and osteonecrosis of the jaw, however, at very low frequency 
[6].  Also, severe suppression of bone turnover is caused by bisphosphonate usage 
[7]. Instead of preventing bone resorption, the opposite strategy for treating 
osteoporosis is the application of anabolic substances such as PTH (1-34) applied in 
intermittent regime [8]. SERMs have been developed and evaluated for osteoporosis 
treatment and prevention, including bazedoxifene, lasofoxifene, droloxifene, 
idoxifene, ormeloxifene, ospemifene, and arzoxifene [9]. Nevertheless, the most 
crucial feature to define the clinical efficacy of a SERM is generally considered to be 
endometrial safety [10].   
A more recent trend is epigenetic drug discovery showing great potential for new 
therapies [11].  Epigenetics refers to transmissible changes in gene expression that 
does not involve changes to the underlying DNA sequence. At least three systems 
including DNA methylation, histone modification and non-coding RNA (ncRNA)-
associated gene silencing are currently considered to initiate and sustain epigenetic 
change [12]. BET (bromodomain and extraterminal domain) proteins are a group of 
epigenetic regulators. They were shown to serve as scaffolds for molecular 
complexes at recognized acetylated histone sites to regulate chromatin accessibility 
to transcription factors and RNA polymerase[13]. They are considered potential 
therapeutic targets in many distinct diseases. The role of epigenetics in osteoporosis 
has just starting to be studied. However, it is gradually being postulated as a key 
concept, as epigenetic mechanisms are involved in the interactions between the 
genome and the environment. The exact relationship between epigenotypes and 
disease phenotypes is still to be elucidated; it is known that epigenetic marks change 
during aging, including a global decrease in the abundance of 5- methylcytosines and 
some histone modification [14]. Since osteoporosis is an age-related disease, it could 
be speculated that those age-related changes in epigenetic marks participate in the 
pathophysiology of the disease [15]. Recent studies demonstrated JQ1 (a 
bromodomain inhibitor developed by the Structural Genomic Consortium) to suppress 
inflammation by a reduction of the inflammatory cytokine release, bone destruction by 
the inhibition of osteoclast maturation and bone formation by the inhibition of 
osteoblast maturation [15, 16]. The latter activity makes its use for the treatment of 
osteoporosis questionable. 
Recently, it was discovered that NMP also exhibits some affinity to bromodomains 
[17]. Over the last years we showed that N-methyl pyrrolidone (NMP), a small water 
soluble molecule used as a constituent in FDA-approved medical devices plays a 
significant role in the osteoblast and osteoclast differentiation [18, 19].  Indeed, NMP 
enhances BMP-2-induced osteoblast differentiation and bone regeneration and 
disrupts osteoclast differentiation and bone resorption. Together these results 
suggest that NMP might act as clinically applicable bromodomain inhibitor and could 
be used for the prevention or treatment of osteoporosis. 
To that end we tested NMP for its ability to inhibit bromodomain binding for a 
variety of BET proteins and for the prevention of osteoporosis in ovariectomized 
(OVX) animals, a well-established animal model mimicking menopause in women 
and simulating osteoporosis.  
 
 
2. Materials and methods 
 
2.1 AlphaScreening Assay.  
AlphaScreening Assay was performed using recombinant bromodomains and 
bromodomain ligands or recombinant BET bromodomains and BET Ligand from BPS 
Bioscience (San Diego, USA). The AlphaScreening signal from the assay is 
correlated with the amount of bromodomain/BET ligand binding to the 
bromodomain.  AlphaScreening signal was measured using EnSpire Alpha 2390 
Multilabel reader (Perkin Elmer). 
Binding experiments were performed in duplicate. AlphaScreening data were 
analyzed using the computer software, Graphpad Prism. In the absence of the 
compound, the AlphaScreening signal (At) in each data set was defined as 100% 
activity. In the absence of the bromodomain/BET Ligand, the AlphaScreening signal 
(Ab) in each data set was defined as 0% activity. The percent activity in the presence 
of each compound was calculated according to the following equation: % activity = 
[(A- Ab)/(At - Ab)]×100, where A= AlphaScreening signal in the presence of the 
compound, Ab =  AlphaScreening signal in the absence of the bromodomain/BET 
Ligand, and At = AlphaScreening signal in the absence of the compound. The percent 
inhibition was calculated according to the following equation: % inhibition = 100 - % 
activity. Values of % activity versus a series of compound concentrations were then 
plotted using non-linear regression analysis of Sigmoidal dose-response curve 
generated with the equation Y=B+(T-B)/1+10
((LogEC50-X)×Hill Slope)
, where Y=percent 
activity, B=minimum percent activity, T=maximum percent activity, X= logarithm of 
compound and Hill Slope=slope factor or Hill coefficient. The IC50 value was 
determined by the concentration causing a half-maximal percent activity. 
 
2.2 Assay of ALP activity and ALP staining 
 
Alkaline phosphatase activity was measured as a marker of osteoblastic 
differentiation. C2C12 cells were purchased from American Type Culture Collection 
(ATCC). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal calf serum (FCS) and antibiotics (100 U/ml penicillin G 
and 100 mg/ml streptomycin). For the experiments, the cells were plated one day 
before treatment and treated with BMP2 in the presence or absence of different 
agents. C2C12 cells were seeded at a density of 5 × 104 cells/cm2 in 24-well plates 
(n = 3 per group) for ALP staining or in 96-well plates (n=4 per group) for ALP 
activity. One day later, cells were treated as indicated in the figure, and incubation 
was continued for 5 more days. After 5 days of incubation, medium was removed, 
and cells were washed with PBS and then scrapped in buffer A (0.56 M 2-amino-2-
methyl-1-propanol). The pellets were then homogenized for 10 s. After centrifugation, 
supernatant was collected and used for ALP assay using p-nitrophenylphosphate as 
a substrate. The protein content of the lysates was measured using Bradford protein 
assay reagent (Bio-Rad). Experiments were performed independently in triplicate. To 
examine alkaline phosphatase activity histochemically, cells were fixed for 10 min 
with 3.7% formaldehyde at room temperature. After washing with PBS, the cells were 
stained as described in [20]. Images of stained cells were captured with a CDD 
camera. 
 
2.3 Osteoporosis Rat Model and Treatments 
 
15 weeks old healthy female Sprague-Dawley (SD) rats (wt. 230 ± 10 g) were 
obtained from Charles River laboratories. The rats were adapted to laboratory 
environment for 2 week before the experiment. In 3 independent experiments a total 
of 30 animals were used. The acclimatized rats underwent either bilateral laparotomy 
(Sham Veh, Ntotal=10) or bilateral ovariectomy (OVX, Ntotal=20). One week after 
recovering from surgery, the OVX rats were divided into 2 groups: OVX with vehicle 
(OVX Veh, Ntotal=10) and OVX with NMP (OVX NMP, 1/3 of LD50 = 
105µl/100g/week, equals an overall concentration of 10.5 mM, Ntotal=10). Treatment 
via intraperitoneal injection was initiated 1 week after OVX and lasted for 15 weeks. 
The body mass of each rat was monitored weekly, and the administered dose was 
adjusted accordingly. All animal procedures were approved by the Animal Ethics 
Committee of the local authorities (Canton Zurich, 40/2012). Whole blood sample 
was collected via abdominal aorta puncture immediately following sacrifice by CO2 
asphyxiation. Then, a serum specimen was harvested after centrifugation (2000 rpm 
for 20 min). Samples were stored at −80°C until further testing and analysis. Femurs 
were dissected and the adherent tissue removed before placing the samples in 70 % 
ethanol and later used for bone mineral density (BMD) measurement and trabecular 
microarchitecture analysis. Liver tissues were also removed and fixed and embedded 
in paraffin (Sophistolab AG, Muttenz, Switzerland) staining with H&E and analyzed 
for pathological changes (toxicity).  
 
2.4 Microcomputed Tomography (µCT) Analysis.  
 
The rat femur samples were measured with a cone-beam microCT (µCT 100, 
SCANCO MEDICAL AG, Brüttisellen, Switzerland) at a resolution of 14.8 µm. The 
reference point was used to define the region of interests (ROI) and the bone was 
automatically segmented, based on its gray scale value in the CT slices. 200 slices 
were evaluated for every sample (volume of interests: VOI). The three-dimensional 
images were reconstructed with the purpose of visualization and display. After 
analyzing the VOI, morphometric bone parameters, including bone volume over total 
volume (BV/TV), trabecular number (Tb.N), trabecular separation (Tb.Sp), trabecular 
thickness (Tb.Th) were obtained. The VOI analysis was performed blindly by the 
same operator. Cortical region of distal femur was also analyzed. The bone was 
automatically segmented, based on its gray scale value in the CT slices. The region 
of interest (cortical bone) was then selected by a contour. The samples were 
segmented based on its gray scale values in the CT slices. 88 slices were evaluated 
for every sample.  
 
 
2.5 Dynamic Histomorphometry 
  
To compare the dynamic rate of bone formation in Sham and OVX rats, 
animals were injected two times with calcein (25 mg/kg, i.p.) 10 days apart. The 
animals were sacrificed 3 days after the second injection and undecalcified calvarias 
were embedded in methyl methacrylate. Coronal Sections (5 μm thickness) of the 
paraxial mesoderm of the calvarial bones were then prepared and three subsequent 
sections were analyzed for each animal. New bone formation was assessed by 
fluorescence microscopy of calcein green using a fluorescein isothiocyanate filter. 
The mineral apposition rate (MAR) was calculated on the basis of interlabeled width 
between the calcein double labelling.  
 
2.6 Histology 
 
Paraffin sections for histological analysis of bone quality were prepared and 
stained with hematoxylin and eosin (H & E) as well as Goldner Trichrome as 
described earlier [19]. The sections were examined for changes in the bone marrow 
and staining was visualized with a Leitz Dialux20 microscope and images captured 
using a Leica camera. 
  
2.7 Serological Analysis of Bone Markers 
  
Serum markers were analyzed to monitor the treatment effect on bone 
physiology. Serum concentration of Estradiol, Osteocalcin (Takara), Cross Linked C-
Telopeptide of Type I Collagen (CTXI) and Protocollagen I N-Terminal Propeptide 
(PINP) (Uscn Life Science) were measured according to the manufacturer’s 
instructions. 
 
2.8 Statistical analysis 
  
All statistical analysis were performed with IBM SPSS statistics 22. Data from 
all parameters were normally distributed (Shapiro-Wilk test). Results are expressed 
as the mean ± SD and were compared by ANOVA and Student's t-test. Results were 
considered significantly different for P<0.05. 
 
 
 
3. Results 
 
 
3.1 Effect of NMP on the binding ability of bromodomains and BET bromodomains 
 
Bromodomain is an evolutionarily conserved, ~110 amino acid motif 
comprised of four left-handed, antiparallel α-helices [21]. The discovery of the 
drugability of bromodomains led to the screening of and identification of small 
molecules which can be used as bromodomain inhibitors in different epigenetic 
mechanisms. To assess the possibility that NMP might act as a bromodomain 
inhibitor, we used an AlphaScreen assay format to determine the effect of NMP on 
the binding ability of different recombinant human bromodomains and recombinant 
human BET bromodomains. By using recombinant human BET, NMP shows slightly 
higher inhibitory effect compared to bromodomains proteins. Indeed, NMP inhibits the 
binding activity of BRD2-BD1BD2 and BRD4-BD1BD2 by 78% and 71% respectively 
(Fig.1A). The pan-BET inhibitor JQ1 was used as control. AlphaScreen dose 
response experiments carried out against BDR2 and BRD4 gave rise to millimolar 
half-maximum inhibitory concentration (IC50) values for NMP and nanomolar for JQ1 
(Fig.1B). Also, NMP+BMP combination resulted in higher ALP activity and staining 
compared to BMP alone and JQ1+BMP (Fig.1C). Since JQ1 was shown to suppress 
inflammation by a reduction of the inflammatory cytokine release and bone 
destruction by the inhibition of osteoclast maturation, we assumed that alongside the 
in vitro effect, NMP could have an in vivo effect on bone remodeling. For that we 
decide to test the effect of NMP on ovariectomy-induced bone loss. 
 
Figure 1: NMP Effect on the binding ability of bromodomains and BET bromodomains: Figure 
1A demonstrates the effect of NMP on the binding ability of recombinant BET bromodomains 
using the AlphaScreening assay where the signal from the assay is correlated with the amount 
of bromodomain/BET ligand binding to the bromodomain. Figure 1B shows the determination 
of millimolar half-maximum inhibitory concentration (IC50) for NMP and nanomolar for (+) JQ1 
on BRD2 and BRD4 binding activity. (C) Effects of NMP and (+) JQ1 on BMP-2-induced ALP 
activity and ALP staining in C2C12 cells are shown (upper panel overview of the cell culture 
well, lower panel higher magnification, lowest panel corresponding ALP activity). 
 
 
3.2 Effects of estrogen deficiency (OVX) on body weights and estradiol levels 
 
To investigate the effect on NMP treatment on ovariectomy induced bone loss, 
we subjected rats to ovariectomy (OVX) and weekly injections of 1/3 of the LD50 
level for NMP based on the weight of the animals [22]. All animals tolerated the 
procedure well and did not show any adverse effects. From the 30 animals used in 3 
independent experiments, one animal of the 3rd round OVX Veh group died in the 
second week of unknown reasons. Therefore, we report here on Sham Veh 
(Ntotal=10), OVX Veh (Ntotal =9) and OVX NMP (Ntotal =10). A Sham NMP group was 
included in pretests but showed no significant difference compared to the Sham Veh 
group (Supplemental figure 1).  In order to confirm that the ovariectomy was effective 
we measured the body weight of the animals weekly. There was no significant 
difference in the mean body weight initially in each group however, after 15 weeks of 
treatment ovariectomy promoted an important increase in body mass over time 
compared to the Sham group (Fig.2A). OVX group on the other hand treated with 
NMP gained significantly less weight than the OVX Veh group. Over the course of 15 
weeks the animals gained weight more rapidly the first 3 weeks and then steadily 
increased over time still keeping a substantial variance between the animal groups at 
all time. Weekly NMP injection to rats for the duration of 15 weeks resulted in no 
toxicological changes in any of the clinical signs; body weight changes and liver 
damage (Supplemental figure 2). Thus, under the present experimental conditions, 
the No Observable Adverse Effect Level (NOAEL) of NMP was assumed to be 
1ml/kg/week for female rats. 
 Figure 2: Body weight changes in the OVX model of osteoporosis: OVX rats received no 
treatment (OVX Veh), OVX NMP rats were treated with 105µl/100g/week of NMP for 15 weeks. 
Sham group was not treated with NMP (A) and estradiol serum level was compared between 
groups (B). Values are mean ± SD; error bars in the figure are presented as SD.   
 
 
Estrogen is an antiresorptive agent which interacts with osteoblasts and 
inhibits osteoclastogenesis leading to bone loss prevention [23]. One of the 
symptoms of menopaused  women is lower estrogen level causing menopause to 
occur [24]. To make sure that the animals were indeed ovariectomized/osteoporotic 
we measured the estradiol level in serum after 15 weeks of treatment. Estradiol 
levels in the OVX Veh group were significantly lower than in Sham Veh (Fig.2B). No 
statistically significant difference in Estradiol level was observed between OVX Veh 
and OVX NMP groups (Fig.2B). Overall these parameters indicate the successful 
establishment of the estrogen deficient animal model. 
 
3.3 Effect of NMP on serum bone markers 
 Fifteen weeks after OVX, analysis of bone markers were performed on serum 
by using ELISA kits for C-terminal cross-linked telopeptides of type I collagen (CTX-
I), N-terminal propeptide of type 1 procollagen (P1NP) and Osteocalcin (OC).   
 
Figure 3: Changes of serum levels of bone markers after ovariectomy: Animals had blood 
drawn and measurements of bone markers in serum were performed.  (A) Change of PINP (B) 
change of CTX-1 and (C) change of Osteocalcin levels in serum. The results of the Sham group 
were compared with OVX Veh group (p<0.05), and the results of the OVX NMP group were 
compared with the results of OVX Veh (P<0.05). Data are mean ± SD.   
 
We found that the levels of all bone markers were higher in OVX Veh group 
compared with those in Sham Veh group (Fig.3). NMP treatment significantly 
lowered the CTX-I and P1NP induced by OVX. Similarly, the increase of OC serum 
level induced by OVX was prevented by treatment with NMP.  
 
3.4 Effects of NMP on bone parameters 
 
Dynamic histomorphometry analysis revealed that NMP had a significant effect 
on bone formation (Fig.4). The level of mineral apposition rate (MAR), a parameter 
that reflects individual osteoblast-mediated bone formation, [25] was significantly 
higher in Sham Veh compared to OVX Veh group (Fig.4). This was also apparent for 
long bones (Supplemental figure 3). In NMP treated OVX group MAR increased 
significantly compared to OVX Veh group. However, the OVX NMP treated group did 
not reach the level of the Sham Veh group.  
 
Figure 4: Dynamic histomorphometry analysis: Imaging of bone formation by fluorescence 
microscopy after calcein double labeling was performed. Two doses of calcein, a fluorochrome 
that incorporates at the site of newly formed bone mineralization, were injected to our animal 
model 10 days apart. The gap between the two green markers represents the amount of new 
bone formed during this time period.  Figure 4A shows calcein double labeling under 
florescence microscope and Figure 4B demonstrates the mineral apposition rate (MAR). P 
values for (OVX Veh vs Sham Veh), and (OVX NMP vs OVX Veh) are provided in the figure.  
 
Static histomorphometry on longitudinal sections of femur was also done with 
hematoxylin and eosin (H&E), and Goldner's Trichrome stain (Fig.5). Bone in the 
metaphysis region, right under the growth plate was analyzed and compared 
between different animal groups (magnification  20). The results support what was 
already observed by the bone markers that NMP treatment prevents bone loss in 
OVX-treated group compared to the control group.  
 
Figure 5: Static histomorphometry: Analyses of rat femur were observed under the microscope 
after specific histomorphometric staining (magnification x 20).  Femoral paraffin sections from 
rats were stained with Hematoxylin and Eosin and Goldner’s Trichrome to visualize and 
compare bone surfaces between the groups. Sections stained with H&E show a clear 
indication of denser trabecular bone in both Sham and OVX treated group compared to OVX 
Veh (A) and Goldner’s trichrome staining, in which mineralized bone matrix was stained green 
while bone marrow and erythrocytes were stained orange/red. In Figure 5B the number of 
trabeculae in OVX Veh was noticeably less allowing for expansion of marrow and adipocytes 
(white gaps). The dotted squares (panel A, C) indicate the area of the histology seen in the 
picture below. 
 
 
3.5 Micro-computed tomography (μCT) 
 
Three-dimensional reconstruction images of the femurs showed differences in 
trabecular microarchitecture among the groups as represented in Figure 6. Analysis 
of different samples indicated that OVX resulted in the deterioration of the trabecular 
bone microarchitecture, as demonstrated by the reduced BV/TV and Tb.N compared 
with the sham group. In contrast, Tb.Sp was significantly increased in response to 
OVX compared to the Sham group. NMP treatment significantly improved the 
microarchitecture deterioration mentioned above, but NMP was not able to reverse 
these parameters to a similar degree as in the Sham Veh group. Cortical bone 
parameters are not significantly different between groups (Supplemental figure 4).  
 
Figure 6: Representative Micro-CT images of trabecular bone microarchitecture in the distal 
femurs: After 15 weeks of treatment femurs from the OVX rats were assessed by microCT for 
different morphometric parameters. OVX Veh animals presented notable reduction in the 
trabecular number, trabecular area, bone mineral density and bone volume compared with 
Sham Veh and OVX NMP rats. Figure 6A represents the 3D reconstruction images of VOI in 
femurs and Figure 6B shows the morphometric bone parameters where the bar graphs 
represent the mean ± SD. P values (Sham Veh versus OVX Veh) and (OVX Veh versus OVX 
NMP) are provided in the figure. 
 
 
4. Discussion  
 
Bromodomains (BRDs) are small protein domains found in a variety of proteins 
which recognize and bind to acetylated histone tails. This specific binding action 
affects chromatin structure and helps the localization of transcriptional complexes to 
specific genes, consequently regulating epigenetically controlled processes including 
gene transcription. Inhibitors of the bromodomain and extra-terminal (BET) proteins, 
BRD and BRDT, which prevent bromodomain binding to acetyl-modified histone tails, 
have shown therapeutic promise in several diseases [26].  
Recently, we showed that N-methyl pyrrolidone (NMP), a small water soluble 
molecule plays a significant role in the osteoblast and osteoclast differentiation [18, 
19]. In the present study we describe the possible role of NMP as a clinically 
applicable bromodomain inhibitor and provide for the first time evidence that NMP 
administered systematically prevents progressive bone loss typically induced in 
osteoporosis. Firstly, NMP was tested on BET family bromodomains to determine its 
affinity towards all BRD subtypes. The study of the impact of NMP on the binding 
capacity of different recombinant human bromodomains and BET showed that this 
small compound is able to inhibit the binding of BRD2 and BRD4 by 70-80%. 
However, the affinity of NMP (milliM range) is much lower than a known selective 
small-molecule bromodomain inhibitor, JQ1 (microM range). Due to this 
characteristic, NMP can be considered a low affinity bromodomain inhibitor. These 
results are consistent with the recently published data showing that NMP is a 
functional acetyl lysine mimetic molecule [17, 27]. 
In many studies, treatment of cells with JQ1 results in cell viability reduction 
and in general inhibition of transcription [28-30]. In contrast, low affinity of NMP 
appears to be less toxic and more beneficial in our system. Indeed, treatment with 
NMP enhances the effect of BMP2 on ALP activity, whereas treatment with JQ1 
causes inhibition of BMP2 induced ALP activity. This suggests that the effect of NMP 
on osteoblast differentiation resulting in a partial inhibition of bromodomain proteins, 
and the complete inhibition as that induced by JQ1 would be deleterious to the effect 
of BMP2 on osteoblastic differentiation. Thus, the high affinity bromodomain inhibitor 
appears not suitable in prevention of osteoporosis, since it inhibits not only osteoclast 
formation but also osteoblast maturation and activity. The low affinity bromodomain 
inhibitor NMP, however, inhibits osteoclast activity at the same concentration as it 
binds to bromodomains of the BET-protein family, enhances osteoblast activity and 
maturation [18, 19].  
On the molecular level JQ1 binds from the BET-protein family predominantly to 
BRD4 [31]. BRD4 has been shown to be depleted from the RUNX2 loci [16] a 
transcription factor involved in the early phase of osteoblast differentiation. NMP by 
its affinity to BRD4 will certainly also interfere with the RUNX2 loci but it can 
apparently overcome this effect on the differentiation of osteoblasts via the 
enhancement of the kinase activity of the BMP-BMP-receptor complex for Smad and 
p38, since osterix, a later osteoblast transcription factor is increased significantly [19]. 
This is in line with BMP2 signaling via Smad to induce dlx5 transcription and via p38 
to induce dlx5 phosphorylation. The phosphorylated dlx5 together with p300 binds to 
the promoter region of osterix to set on osterix transcription [32]. Therefore, the 
enhanced phosphorylation of Smad and p38 by NMP [19] is sufficient for an increase 
in osterix phosphorylation independent of Runx2 transcription which is most likely 
decreased by the binding of NMP to the bromodomain of Brd4 (Fig. 1).  
Moreover, JQ1 also inhibits osteoclast differentiation by interfering with BRD4-
dependent RANKL activation of NFATC1 transcription [16]. NMP was also shown to 
inhibit RANKL activation of NFATC1 transcription [18] most likely in a BRD4 
dependent fashion enhanced by blocking ERK phosphorylation which reduces cFos 
transcription and AP-1 activation and with it an additional pathway for the induction of 
NFATC1 transcription. 
Due to the in vitro effect of NMP on bone remodeling, we decided to evaluate 
its potential anti-osteoporotic effect on estrogen-deficiency induced osteoporosis. The 
ovariectomized rat model is a well-established model for estrogen-deficiency induced 
bone loss and has been previously used by a large number of researchers to test 
drugs for osteoporosis treatment and prevention [33-35].  
It is well known that estrogen deficiency induces body fat accumulation and 
subsequently causes an increase in body weight [36]. Heine et al. demonstrated that 
estrogen receptor (ER) knockout mice have higher fat mass and lower energy 
expenditure than wild-type mice [37]. Estrogen may be involved directly in energy 
metabolism by binding to the ER within the abdominal and subcutaneous fat tissue 
[38]. In our experiments, subcutaneous administration of NMP did not significantly 
affect serum estradiol concentration. However, NMP did lower body weight gain in 
OVX rats. These results suggest that, NMP might have anti-osteoporotic effects in 
OVX rats, without the influence on hormone levels such as from estrogen. 
Bone loss after ovariectomy is associated with high bone turnover where bone 
resorption exceeds bone formation. Subcutaneous injection of NMP significantly 
decreased CTX-1, and OC levels compared to an OVX-control group, suggesting that 
NMP decreased bone turnover induced by OVX. Furthermore, dynamic 
histomorphometry analysis shows that NMP increases new bone formation. 
The most important parameter related to fracture risk is the mechanical 
strength of bones. The composition of long bones differs depending on the area. The 
midshaft region is dominated by cortical bone whereas the proximal femur is 
dominated by cancellous bone [39].  The effect of menopause or ovariectomy is more 
pronounced on cancellous than cortical bone [40]. Due to the limited examination 
time of 15 weeks we mainly saw changes in cancellous bone. One could speculate 
that over extended time periods we might have seen OVX induced cortical bone 
destruction and preservation with NMP, since advanced postmenopausal women 
with osteopenia and fractures show significant effect also in the cortical bone [41].  
In the present study, we established that NMP treatment effectively protected 
against loss of bone density by estrogen depletion. Since BMD has been described 
as only a substitute measure of bone strength, [42] microarchitecture determinants 
are necessary to evaluate the real impact of a treatment on  trabecular bone quality. 
Femoral microarchitecture analyzed by micro-CT revealed that NMP treatment could 
prevent deterioration of the bone volume/tissue volume (BV/TV), trabecular number 
(Tb.N), and decrease trabecular space (Tb.Sp) parameters compared to the OVX 
Veh control. The results suggested a moderate but significant effect of NMP on 
trabecular microarchitectural properties preservation. These findings are in 
agreement with other authors and drugs that were unable to completely restore the 
trabecular bone structure after its deterioration had occurred, emphasizing the need 
for prevention of trabecular bone loss. It has been suggested that bone resorption is 
increased with oxidative stress by promoting osteoclastic differentiation. Also, the 
toxicity of NMP must be evaluated before it can be used in the development of a drug 
or supplement. In this study, subcutaneous injection of NMP caused no changes that 
could be considered toxicologically significant.  
In conclusion our results show that NMP, a nontoxic, inexpensive compound already 
used as a constituent in FDA-approved medical devices, possesses significant anti-
osteoporotic activity in OVX rats. It improved both mass and quality of bones in OVX 
rat. The bone sparing action of NMP may be associated with its characteristic as a 
low affinity bromodomain inhibitor in conjunction with the enhancement of Smad and 
p38 phosphorylation in osteoblasts to overcome the inhibition of osteoblast 
differentiation and inhibition of ERK phosphorylation in preosteoclasts to enhance the 
inhibition of osteoclast differentiation even further.  Since NMP influences the 
osteoblasts/osteoclasts balance in vitro and shows an anti-osteoporotic effect in vivo, 
it can help postmenopausal women from losing bone mass. Overall, NMP seems to 
be a potential candidate for the application of epigenetics as new mechanism for 
osteoporosis treatment without any serious side effects.   
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